Torcetrapib and Rimonabant-Acomplia: Promising Next-Generation "Good" Cholesterol Raising Drugs - PRWeb Press Release Group http://www.rsspad.com/rss2/13155.xml NEW YORK: Based on compelling evidence that raising high-density lipoprotein cholesterol levels (HDL-C, also known as "good" cholesterol) helps halt atherosclerosis, pharmaceutical companies are racing to produce the next generation of medications to replace the ineffectual ones currently on the market. Niacin, the current drug of choice, increases HDL-C by only 15% to 35%, and then only at daily doses 3 grams or higher, increasing the chance for unpleasant side effects. - Powered by PRWeb and RSSPad en xml@emediawire.com xml@emediawire.com 30 Torcetrapib and Rimonabant-Acomplia: Promising Next-Generation "Good" Cholesterol Raising Drugs http://www.prweb.com/releases/2006/11/prweb477786.htm Based on compelling evidence that raising high-density lipoprotein cholesterol levels (HDL-C, also known as "good" cholesterol) helps halt atherosclerosis, pharmaceutical companies are racing to produce the next generation of medications to replace the ineffectual ones currently on the market. Niacin, the current drug of choice, increases HDL-C by only 15% to 35%, and then only at daily doses three grams or higher, increasing the chance for unpleasant side effects. (PRWeb Nov 17, 2006)

Read the full story at http://www.prweb.com/releases/2006/11/prweb477786.htm

]]> Fri, 17 Nov 2006 08:00:00 GMThttp://www.prweb.com/releases/2006/11/prweb477786.htm